Increased percentages of tumor necrosis factor-α+/ interferon-T+lymphocytes and calprotectin+/tumor necrosis factor-A+ monocytes in patients with acute Kawasaki disease

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 1, 2012, Pages 99-105

  Guggino, G ^a   Cimaz, R ^b   Accomando, S ^a   Pagnini, I ^b   Simonini, G ^b   Di Liberto, D ^a   De Martino, M ^b   Dieli, F ^a   Sireci, Guido ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Calprotectin; Kawasaki disease; Monocytes; TNF

Indexed keywords

CALGRANULIN; COMPLEMENT FACTOR H; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL PROTEIN; CD14 ANTIGEN; CD3 ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; IN VITRO STUDY; INFANT; MALE; MONOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; STAINING; STREPTOCOCCUS; T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CROSS REACTION; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; FEVER; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION;

EID: 84861464164     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500112     Document Type: Article

References (13)

1. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010; 8:197-203.
2. Foell D, Ichida F, Vogl T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003; 361:1270-2. (Pubitemid 36428584)
3. Leung DY, Schlievert PM, Meissner HC. The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum 1998; 41:1538-47. (Pubitemid 28459911)
4. Song MS, Lee SB, Sohn S, et al. Infliximab treatment for refractory kawasaki disease in korean children. Korean Circ J 2010; 40:334-8.
5. Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011; 161:494-9.
6. Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005; 174:5837-45. (Pubitemid 40593229)
7. Hirono K, Foell D, Xing Y, et al. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol 2006; 48:1257-64. (Pubitemid 44345126)
8. Ohkuni H, Todome Y, Mizuse M, et al. Biologically active extracellular products of oral viridans streptococci and the aetiology of Kawasaki disease. J Med Microbiol 1993; 39:352-62. (Pubitemid 23356041)
9. Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A, Zipfel PF. Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans. J Biol Chem 2007; 282:37537-44.
10. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936-41.
11. Sheikh SZ, Plevy SE. The role of the macrophage in sentinel responses in intestinal immunity. Curr Opin Gastroenterol 2010; 26:578-82.
12. Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 2010;58:355-64.
13. Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clin Exp Immunol 2011; 164:20-2.